Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Journal of Nuclear Medicine, 65, 1, S. 79-84

Event: Veröffentlichung

(where): Augsburg

(who): Universität Augsburg

(when): 2024

Event: Veröffentlichung

(who): Society of Nuclear Medicine

(when): 2024

Creator: Steinhelfer, Lisa
Lunger, Lukas
Cala, Lisena
Pfob, Christian H.
Lapa, Constantin Frederik Victor
Hartrampf, Philipp E.
Buck, Andreas K.
Schäfer, Hannah
Schmaderer, Christoph
Tauber, Robert
Brosch-Lenz, Julia
Haller, Bernhard
Meissner, Valentin H.
Knorr, Karina
Weber, Wolfgang A.
Eiber, Matthias

DOI: 10.2967/jnumed.123.265986

URN: urn:nbn:de:bvb:384-opus4-1118098

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:03 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Steinhelfer, Lisa
Lunger, Lukas
Cala, Lisena
Pfob, Christian H.
Lapa, Constantin Frederik Victor
Hartrampf, Philipp E.
Buck, Andreas K.
Schäfer, Hannah
Schmaderer, Christoph
Tauber, Robert
Brosch-Lenz, Julia
Haller, Bernhard
Meissner, Valentin H.
Knorr, Karina
Weber, Wolfgang A.
Eiber, Matthias
Universität Augsburg
Society of Nuclear Medicine

Time of origin

2024

Other Objects (12)

Hochschulschrift

Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

$Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [$^177}$Lu]Lu-PSMA I&T$

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [$^177}$Lu]Lu-PSMA I&T

Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome

Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients

Hochschulschrift

Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

$Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [$^177}$Lu]Lu-PSMA I&T$

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [$^177}$Lu]Lu-PSMA I&T

Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome

Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients

Hochschulschrift

Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

$Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [$^177}$Lu]Lu-PSMA I&T$

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [$^177}$Lu]Lu-PSMA I&T

Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome

Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T

Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome

Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients

Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T

Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome

Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients

Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T

Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome

Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients

Related objects

Reset password